24 episodes

A podcast detailing current topics in the Journal of Clinical Psychopharmacology.

The Journal of Clinical Psychopharmacology Podcast The Journal of Clinical Psychopharmacology

    • Health & Fitness
    • 4.5 • 8 Ratings

A podcast detailing current topics in the Journal of Clinical Psychopharmacology.

    Real-World Clinical Practice Among Patients With Bipolar Disorder and Chronic Kidney Disease on Long-term Lithium Therapy

    Real-World Clinical Practice Among Patients With Bipolar Disorder and Chronic Kidney Disease on Long-term Lithium Therapy

    Lithium is considered a standard treatment for bipolar disorder, but it remains underprescribed, in part because of its association with kidney dysfunction.
    In this podcast, Dr. Balwinder Singh discusses an article he and his colleagues published in the January-February 2023 issue of the Journal of Clinical Psychopharmacology on “real-world” clinical practice involving patients with bipolar disorder (BD) and chronic kidney disease (CKD). In their study, patients with BD and CKD who discontinued lithium use after CKD diagnosis had a higher risk for a relapse of their mood disorder as well as a shorter time to the first mood episode, suggesting a need for more thorough discussion before discontinuing lithium after a diagnosis of CKD.

    • 8 min
    Endoxifen Approval for Bipolar Disorder in India: A Premature or a Pragmatic Decision?

    Endoxifen Approval for Bipolar Disorder in India: A Premature or a Pragmatic Decision?

    In a commentary published in the Journal of Clinical Psychopharmacology, Dr. Rishab Gupta (Brigham and Women's Hospital/Harvard Medical School) and Dr. Swarndeep Singh (Government Medical College and Hospital, Chandigarh, India) cast a critical eye on India’s regulatory approval for the use of endoxifen for the treatment of manic episodes in patients with bipolar disorder type 1. In their article and in this podcast, they suggest that there are important deficiencies in the research that was used to support the regulatory approval. No other country has approved endoxifen for treating bipolar disorder. They caution that endoxifen should be considered as an option to treat acute mania only after a careful consideration of risks/benefits with the patient and their family and after providing them with a list of alternative medications.

    • 5 min
    Psychedelics in the Treatment of Depression: A Critical Appraisal of Evidence

    Psychedelics in the Treatment of Depression: A Critical Appraisal of Evidence

    Psychedelics as a potential treatment for depression is an irresistible topic in the mainstream press, but what is the evidence base for their use? In this podcast, psychiatrist and journal Digital Editor Dr. Julia Ann Koretski (of Mass General Brigham Newton-Wellesley Hospital) leads Dr. Ishrat Husain and Dr. Richard Balon through an illuminating discussion of where we stand in clinical trials research and the important limitations of current findings. Dr. Husain is the senior author of “A Critical Appraisal of Evidence on the Efficacy and Safety of Serotonergic Psychedelic Drugs as Emerging Antidepressants: Mind the Evidence Gap” in the November-December 2022 issue of the journal (Volume 42, Issue 6). He is a psychiatrist and researcher at the Center for Addiction and Mental Health in Toronto. Dr. Balon, Associate Editor of the journal and psychiatrist at Wayne State University in Detroit, is author of the accompanying editorial, “Are Magic Mushrooms Really Magic? Psilocybin in the Treatment of Depression.”

    • 24 min
    The Modernization of Clozapine: A Recapitulation of the Past in the United States and the View Forward

    The Modernization of Clozapine: A Recapitulation of the Past in the United States and the View Forward

    In this podcast, Dr. Jonathan Leung discusses the article, “The Modernization of Clozapine: A Recapitulation of the Past in the United States and the View Forward,” published with several colleagues in the November-December 2022 issue of the Journal of Clinical Psychopharmacology (Volume 42, Issue 6). Dr. Leung, lead author of the review article, is a psychiatric pharmacist at the Mayo Clinic in Rochester, MN, and faculty member at the Mayo Clinic College of Medicine. Clozapine is a unique life-saving drug for treatment-resistant schizophrenia and reduction in risk of recurrent suicidal behavior in schizophrenia or schizoaffective disorder, but it is underused in the United States despite its established efficacy. Clozapine’s benefits for reduction of suicidality may extend to other uses as well, although more rigorous studies are needed. The article and podcast discuss the history of FDA approval for clozapine, hematologic monitoring requirements that have been viewed as cumbersome, as well as other barriers related to clozapine use.

    • 13 min
    Effects of Selective Serotonin Reuptake Inhibitor Use on MDMA–Assisted Therapy for Posttraumatic Stress Disorder

    Effects of Selective Serotonin Reuptake Inhibitor Use on MDMA–Assisted Therapy for Posttraumatic Stress Disorder

    In small-scale studies, 3,4-methylenedioxymethamphetamine (MDMA)-assisted therapy for posttraumatic stress disorder has shown some promise, but exploratory analyses have suggested that recent use of selective serotonin reuptake inhibitors (SSRIs) can dampen the efficacy of this novel therapy. In this podcast, Dr. Collin M. Price, a psychiatric resident at UCLA, and Dr. Allison Feduccia, a neuropharmacologist and CEO of a company that curates CME courses on psychedelics, discuss their new article in the Journal of Clinical Psychopharmacology that provides a selective review of the literature in the basic and clinical neurosciences relevant to the interaction of SSRIs and MDMA. They suggest that there is an urgent need for future work dedicated to addressing this important clinical topic. Their article is published in the September-October 2022 issue of the journal.

    • 12 min
    Exposure to SARS-CoV-2, Acute Kidney Injury, and Lithium Toxicity

    Exposure to SARS-CoV-2, Acute Kidney Injury, and Lithium Toxicity

    In this podcast, Dr. Melvin McInnis discusses lithium toxicity in individuals with bipolar disorder who were infected by the SARS-CoV-2 virus. Lithium is an effective long-term management strategy for treating bipolar disorder, but because acute kidney damage can be a complication of COVID-19, the body’s ability to process lithium may be affected. Based on his case report study, coauthored by Dr. Anastasia Yocum and published in the September-October 2022 issue of the Journal of Clinical Psychopharmacology, Dr. McInnis urges proactive monitoring for signs of diminished kidney functions to avoid levels of toxicity, especially during the pandemic.

    • 6 min

Customer Reviews

4.5 out of 5
8 Ratings

8 Ratings

BeeBee0125 ,

Informative

Good content, but increasing the rate of everyone’s speech makes it hard to listen to.

Top Podcasts In Health & Fitness

Scicomm Media
Jay Shetty
Ten Percent Happier
Ri Turner
Aubrey Gordon & Michael Hobbes
Peter Attia, MD

You Might Also Like

Psychopharmacology Institute
Neuroscience Education Institute
Pocket Psychiatry: A Carlat Podcast
David Puder, M.D.
Eric Christianson, PharmD; Pharmacology Expert and Clinical Pharmacist
Craig Heacock MD